1 - 20 toradh á dtaispeáint as 49 toradh san iomlán ar an gcuardach 'Lionel Adès', am iarratais: 0.09s Beachtaigh na torthaí
  1. 1
    High-risk MDS after HMAs

    High-risk MDS after HMAs de réir Lionel Adès

    Foilsithe / Cruthaithe 2019-06-01
    Faigh an téacs iomlán
    Alt
  2. 2
    TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.

    TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS. de réir Lionel Ades, Charicleia Kelaidi, Pierre Fenaux

    Foilsithe / Cruthaithe 2011-01-01
    Faigh an téacs iomlán
    Alt
  3. 3
    TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.

    TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS. de réir Charicleia Kelaidi, Lionel Ades, Pierre Fenaux

    Foilsithe / Cruthaithe 2011-09-01
    Faigh an téacs iomlán
    Alt
  4. 4
    Aging and malignant hemopathies

    Aging and malignant hemopathies de réir Dominique Bron, Lionel Ades, Tamas Fulop, Valentin Goede

    Foilsithe / Cruthaithe 2015-05-01
    Faigh an téacs iomlán
    Alt
  5. 5
    Aging and blood disorders: new perspectives, new challenges

    Aging and blood disorders: new perspectives, new challenges de réir Dominique Bron, Lionel Ades, Tamas Fulop, Valentin Goede, Reinhard Stauder

    Foilsithe / Cruthaithe 2015-04-01
    Faigh an téacs iomlán
    Alt
  6. 6
    Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes

    Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes de réir Vincent Jachiet, Pierre Fenaux, Anna Sevoyan, Yervand Hakobyan, Lionel Ades, Olivier Fain, Arsène Mekinian, on behalf of the MINHEMON and GFM

    Foilsithe / Cruthaithe 2021-05-01
    Faigh an téacs iomlán
    Alt
  7. 7
    Machine learning-based improvement of MDS-CBC score brings platelets into the limelight to optimize smear review in the hematology laboratory

    Machine learning-based improvement of MDS-CBC score brings platelets into the limelight to optimize smear review in the hematology laboratory de réir Jaja Zhu, Pierre Lemaire, Stéphanie Mathis, Emily Ronez, Sylvain Clauser, Katayoun Jondeau, Pierre Fenaux, Lionel Adès, Valérie Bardet

    Foilsithe / Cruthaithe 2022-09-01
    Faigh an téacs iomlán
    Alt
  8. 8
    Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease

    Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease de réir Marie-Camille Lafargue, Mickaël Bobot, Helmut G. Rennke, Marie Essig, Martin Carre, Lucile Mercadal, Jonathan Farhi, Hamza Sakhi, Thibault Comont, Léonard Golbin, Pierre Isnard, Jonathan Chemouny, Nathalie Cambier, Kamel Laribi, Umut Selamet, Leonardo V. Riella, Olivier Fain, Lionel Adès, Pierre Fenaux, Camille Cohen, Arsène Mekinian, Marie-Camille Lafargue, Mickaël Bobot, Thibault Comont, Nathalie Cambier, Kamel Laribi, Olivier Fain, Lionel Adès, Pierre Fenaux, Arsène Mekinian, Thibault Comont, Nathalie Cambier, Kamel Laribi, Olivier Fain, Lionel Adès, Pierre Fenaux, Arsène Mekinian, Thibault Comont, Olivier Fain, Lionel Adès, Pierre Fenaux, Arsène Mekinian

    Foilsithe / Cruthaithe 2023-12-01
    Faigh an téacs iomlán
    Alt
  9. 9
    Slow relapse in acute myeloid leukemia with inv(16) or t(16;16)

    Slow relapse in acute myeloid leukemia with inv(16) or t(16;16) de réir Thomas Clozel, Aline Renneville, Marion Venot, Claude Gardin, Charikleia Kelaidi, Geneviève Leroux, Virginie Eclache, Claude Preudhomme, Pierre Fenaux, Lionel Adès

    Foilsithe / Cruthaithe 2009-10-01
    Faigh an téacs iomlán
    Alt
  10. 10
    A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM)

    A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe... de réir Lionel Ades, Agnès Guerci-Bresler, Pascale Cony-Makhoul, Laurence Legros, Marie Sebert, Thorsten Braun, Jacques Delaunay, Kristell Desseaux, Sylvie Chevret, Pierre Fenaux

    Foilsithe / Cruthaithe 2019-04-01
    Faigh an téacs iomlán
    Alt
  11. 11
    Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

    Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes de réir Joshua F. Zeidner, Flora Mazerolle, Jonathan Norton, Antoine Regnault, Fjoralba Kristo, Heather Romero, Robert J. Fram, Douglas V. Faller, Mehul Dalal, Lionel Ades, Mikkael A. Sekeres

    Foilsithe / Cruthaithe 2022-12-01
    Faigh an téacs iomlán
    Alt
  12. 12
    Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes

    Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes de réir Thomas Cluzeau, Kathy L. McGraw, Brittany Irvine, Erico Masala, Lionel Ades, Ashley A. Basiorka, Jaroslaw Maciejewski, Patrick Auberger, Sheng Wei, Pierre Fenaux, Valeria Santini, Alan List

    Foilsithe / Cruthaithe 2017-12-01
    Faigh an téacs iomlán
    Alt
  13. 13
    Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications.

    Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications. de réir Sofiane Fodil, Sylvie Chevret, Camille Rouzaud, Sandrine Valade, Florence Rabian, Eric Mariotte, Emmanuel Raffoux, Raphael Itzykson, Nicolas Boissel, Marie Sébert, Lionel Adès, Lara Zafrani, Elie Azoulay, Etienne Lengliné

    Foilsithe / Cruthaithe 2022-01-01
    Faigh an téacs iomlán
    Alt
  14. 14
    NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents

    NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents de réir Pedro Henrique Prata, Cécile Bally, Thomas Prebet, Christian Recher, Geoffroy Venton, Xavier Thomas, Emmanuel Raffoux, Arnaud Pigneux, Thomas Cluzeau, Judith Desoutter, Julie Gay, Claude Preudhomme, Pierre Fenaux, Lionel Adès

    Foilsithe / Cruthaithe 2018-10-01
    Faigh an téacs iomlán
    Alt
  15. 15
    Very long-term remission with azacitidine in VEXAS syndrome

    Very long-term remission with azacitidine in VEXAS syndrome de réir Lin-Pierre Zhao, Vincent Jachiet, Olivier Kosmider, Lise Larcher, Emmanuelle Clappier, Marie Sébert, Lionel Adès, Pierre Hirsch, Thibault Mahévas, Maxime Battistella, Jean-David Bouaziz, Arsène Mekinian, Pierre Fenaux, MINHEMON FRENVEX

    Foilsithe / Cruthaithe 2025-01-01
    Faigh an téacs iomlán
    Alt
  16. 16
    Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia

    Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia de réir Jacqueline Lehmann-Che, Cécile Bally, Eric Letouzé, Caroline Berthier, Hao Yuan, Florence Jollivet, Lionel Ades, Bruno Cassinat, Pierre Hirsch, Arnaud Pigneux, Marie-Joelle Mozziconacci, Scott Kogan, Pierre Fenaux, Hugues de Thé

    Foilsithe / Cruthaithe 2018-05-01
    Faigh an téacs iomlán
    Alt
  17. 17
    Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M

    Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M de réir David Fandrei, Tony Huynh, Marie Sébert, Lorea Aguinaga, Valeria Bisio, Rathana Kim, Emmanuelle Clappier, Marion Espéli, Karl Balabanian, Hélène Moins-Teisserenc, Antoine Toubert, Nicolas Dulphy, Pierre Fenaux, Lionel Adès, Lin-Pierre Zhao

    Foilsithe / Cruthaithe 2023-12-01
    Faigh an téacs iomlán
    Alt
  18. 18
    Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

    Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia de réir Brian Ball, Rami S. Komrokji, Lionel Adès, Mikkael A. Sekeres, Amy E. DeZern, Lisa Pleyer, Norbert Vey, Antonio Almeida, Ulrich Germing, Thomas Cluzeau, Uwe Platzbecker, Steven D. Gore, Pierre Fenaux, Thomas Prebet

    Foilsithe / Cruthaithe 2018-08-01
    Faigh an téacs iomlán
    Alt
  19. 19
    Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial)

    Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a repor... de réir Ramy Rahmé, Lionel Ades, Xavier Thomas, Agnès Guerci-Bresler, Arnaud Pigneux, Norbert Vey, Emmanuel Raffoux, Sylvie Castaigne, Olivier Spertini, Sebastian Wittnebel, Jean Pierre Marolleau, Gandhi Damaj, Dominique Bordessoule, Julie Lejeune, Sylvie Chevret, Pierre Fenaux

    Foilsithe / Cruthaithe 2018-11-01
    Faigh an téacs iomlán
    Alt
  20. 20
    Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia

    Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia de réir Nabih Maslah, Norman Salomao, Louis Drevon, Emmanuelle Verger, Nicolas Partouche, Pierre Ly, Philippe Aubin, Nadia Naoui, Marie-Helene Schlageter, Cecile Bally, Elsa Miekoutima, Ramy Rahmé, Jacqueline Lehmann-Che, Lionel Ades, Pierre Fenaux, Bruno Cassinat, Stephane Giraudier

    Foilsithe / Cruthaithe 2020-06-01
    Faigh an téacs iomlán
    Alt

Uirlisí cuardaigh: